Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease | Zendy

Xiangyu Wang | Zendy; Huijie Zhang | Zendy; Qian Zhang | Zendy; Meiping Guan | Zendy; Shuyue Sheng | Zendy; Wei Mo | Zendy; Mengchen Zou | Zendy; Jimin Li | Zendy; Jianlu Bi | Zendy; Xianyu Tang | Zendy; Huiyan Zeng | Zendy; Jiali He | Zendy; Gugen Xu | Zendy; Ping Li | Zendy; Yaoming Xue | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease

Author(s) -

Xiangyu Wang,

Huijie Zhang,

Qian Zhang,

Meiping Guan,

Shuyue Sheng,

Wei Mo,

Mengchen Zou,

Jimin Li,

Jianlu Bi,

Xianyu Tang,

Huiyan Zeng,

Jiali He,

Gugen Xu,

Ping Li,

Yaoming Xue

Publication year - 2020

Publication title -

american journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 85

eISSN - 1421-9670

pISSN - 0250-8095

DOI - 10.1159/000510255

Subject(s) - medicine , exenatide , insulin lispro , renal function , insulin glargine , endocrinology , type 2 diabetes , kidney disease , dulaglutide , urology , diabetes mellitus , lixisenatide , albuminuria , hypoglycemia , gastroenterology

Cardiovascular outcomes in clinical trials with type 2 diabetes mellitus (T2DM) patients have shown that glucagon-like peptide-1 receptor agonist can have a beneficial effect on the kidney. This trial aimed to assess the effects of exenatide on renal outcomes in patients with T2DM and diabetic kidney disease (DKD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research